Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (WXIBF)
OTHER OTC:WXIBF
RESEARCH TOOLSreports
Wuxi Biologics (Cayman) (WXIBF) Stock Price & Analysis
114 Followers
WXIBF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.55 - $6.60
Previous Close$1.87
Volume50.05K
Average Volume (3M)55.75K
Market Cap
$7.71B
Enterprise Value$7.10B
Total Cash (Recent Filing)¥9.86B
Total Debt (Recent Filing)¥4.40B
Price to Earnings (P/E)16.2
Beta0.62
Next Earnings
Aug 19, 2024EPS Estimate
$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding4,259,278,169
10 Day Avg. Volume5,265
30 Day Avg. Volume55,749
Standard Deviation0.17
R-Squared0.01
Alpha-0.00163
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.46Price Target Upside71.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Wuxi Biologics (Cayman) News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceWuxi Bio's strong free cash flow and reduced capital expenditure needs suggest the potential for starting dividend payments, offering an attractive yield to shareholders.
Market ValuationWuxi Bio is currently trading at a price-to-book ratio significantly lower than its peers, indicating potential undervaluation and room for stock price growth.
Shareholder ValueThe possibility of a share buyback or company sale provides multiple pathways for Wuxi Bio to enhance shareholder value.
Bears Say
Financial PerformanceNon-COVID revenue in China slightly declined by 1.2% year-over-year in 2023 due to biotech funding constraints.
Legislation ImpactThe House version would lead to all US contracts stopping, potentially impacting Wuxi Bio's revenue and stock value negatively.
Regulatory RiskBiosecure Act may be approved, which puts greater than 50% of the company’s business at risk.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
10.71% Mutual Funds
6.93% Other Institutional Investors
82.36% Public Companies and
Individual Investors
WXIBF FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was $1.55 and its highest was $6.60 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Currently, no data Available
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 19, 2024 which is in 96 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 26, 2024. The company reported $0.036 earnings per share for the quarter, missing the consensus estimate of $0.037 by >-$0.001.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is $0.06.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,260,615,700 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of $0.036 in its last earnings report, missing expectations of $0.037. Following the earnings report the stock price went down -2.247%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Among the largest hedge funds holding Wuxi Biologics (Cayman) Inc.’s share is Gilder Gagnon Howe & Co LLC.. It holds Wuxi Biologics (Cayman) Inc.’s shares valued at N/A.
---
Wuxi Biologics (Cayman) Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.46 (71.29% Upside)
$3.46 (71.29% Upside)
Hedge Fund Trend
Decreased
By 8.3M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.14%
12-Months-Change
Fundamentals
Return on Equity
9.01%
Trailing 12-Months
Asset Growth
11.88%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
---
WXIBF Stock 12 Month Forecast
Average Price Target
$3.46
▲(71.29% Upside)
Technical Analysis
Best Analysts Covering WXIBF
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-30.10%
reiterated a buy rating 3 days ago
Copying Chris Lui's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -30.10% per trade.
---